A Single Dose Study Of PF-04620110 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Healthy
Interventions
DRUG

PF-04620110

"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Pfizer

INDUSTRY